OX40L fusion proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-9718870-B2
Application number	US-201514722679-A
Country	US
Kind code	B2
Filing date	May 27, 2015
Priority date	May 29, 2014
Publication date	Aug 1, 2017
Grant date	Aug 1, 2017

Abstract

The disclosure provides OX40L huIgG4 fusion polypeptide subunits comprising a human IgG4 Fc domain, a trimerization domain, and the receptor binding domain of Ox40 ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.

First claim

What is claimed is:

1. A single-chain polypeptide subunit comprising: a human IgG4 Fc domain; a functional trimerization domain; and a receptor binding domain of OX40L, wherein the polypeptide subunit further comprises, from the amino terminus to the carboxy terminus, the human IgG4 Fc domain, followed by the trimerization domain, followed by the OX40L receptor binding domain, wherein the polypeptide subunit can self-assemble into a trimeric or hexameric protein, and wherein the polypeptide subunit comprises the amino acid sequence of SEQ ID NO: 4.

2. The polypeptide subunit of claim 1 , wherein a hexameric protein assembled from six of the polypeptide subunits can specifically bind to human OX40.

3. The polypeptide subunit of claim 1 , further comprising an associated heterologous agent.

4. The polypeptide subunit of claim 3 , wherein the heterologous agent is a heterologous polypeptide and is fused to the polypeptide subunit via a peptide bond.

5. The polypeptide subunit of claim 4 , wherein the heterologous polypeptide is fused to the N-terminus of the IgG4-Fc domain, is fused to the C-terminus of the receptor binding domain of OX40L, is fused to the C-terminus of the IgG4-Fc domain and to the N-terminus of the trimerization domain, or is fused to the C-terminus of the trimerization domain and to the N-terminus of the receptor binding domain of OX40L.

6. The polypeptide subunit of claim 3 , wherein the heterologous agent is chemically conjugated to the polypeptide subunit.

7. The polypeptide subunit of claim 3 , wherein the heterologous agent comprises a cytotoxic molecule, a stabilizing agent, an immune response modifier, or a detectable agent.

8. A trimeric protein comprising three polypeptide subunits of claim 1 .

9. A hexameric protein comprising six polypeptide subunits of claim 1 .

10. The hexameric protein of claim 9 comprising OX40L IgG4P Fusion Protein.

11. A composition comprising the hexameric protein of claim 9 , and a carrier.

12. A polynucleotide comprising a nucleic acid that encodes the polypeptide subunit of claim 1 , or the hexameric protein of claim 9 .

13. The polynucleotide of claim 12 , comprising SEQ ID NO: 3.

14. A vector comprising the polynucleotide of claim 12 or claim 13 .

15. A host cell comprising the polynucleotide of claim 12 or claim 13 or the vector of claim 14 .

16. A method of producing the polypeptide subunit of claim 1 or the hexameric protein of claim 9 , comprising culturing the host cell of claim 15 under conditions in which the polypeptide subunit or hexameric protein encoded by the polynucleotide is expressed, and recovering the polypeptide subunit or hexameric protein.

17. A method to promote survival or proliferation of activated T cells, comprising contacting activated T cells with the hexameric protein of claim 9 , wherein the hexameric protein can specifically bind to OX40 on the surface of the T cells.

18. A method to reduce regulatory T cell (Treg)-mediated suppression of activated T cell proliferation, comprising contacting a mixture of activated T cells and Treg cells with the hexameric protein of claim 9 , wherein the hexameric protein can specifically bind to OX40 on the surface of the T cells.

19. A method of inducing cytokine release from activated T cells, wherein the cytokine is selected from the group consisting of IFNγ, TNFα, IL-10, IL-13 or any combination thereof, comprising contacting activated T cells with the hexameric protein of claim 9 , wherein the hexameric protein can specifically bind to OX40 on the surface of the T cells.

20. The method of claim 19 , wherein the cytokine is selected from the group consisting of IFNγ, TNFα, IL-10, IL-13 or any combination thereof.

21. The method of claim 17 , wherein the activated T cells are activated CD4+ T cells, activated CD8+ T cells, or a combination thereof.

22. The method of any one of claim 21 , wherein the activated CD4+ T cells are human CD4+ T cells, cynomolgus monkey CD4+ T cells, rhesus monkey CD4+ T cells, or a combination thereof.

23. A method of promoting T cell activation, comprising contacting T cells with the hexameric protein of claim 9 , wherein the hexameric protein can specifically bind to OX40 on the surface of the T cells.

24. The method of claim 23 , further comprising cross-linking of the hexameric protein through interaction of the IgG4-Fc domain with a cell expressing FcγR.

25. The method of claim 24 , wherein the cell expressing FcγR is a B cell, a monocyte, a macrophage, a myeloid or plasmacytoid dendritic cell, a follicular dendritic cell, a Langerhans cell, an endothelial cell, an NK cell, an activated T cell, a neutrophil, a eosinophil, a platelet, a mast cell, a CD45+ cell from a primary human tumor or tumor-draining or non-draining lymph node, a CD45+ cell from other secondary or tertiary lymphoid structures, or a combination thereof.

26. The method of claim 23 , wherein T cell activation can be measured through stimulation of the NFκB signal transduction pathway.

27. The method of claim 23 , wherein the activated T cells are activated CD4+ T cells, activated CD8+ T cells, or a combination thereof.

28. The method of claim 27 , wherein the activated CD4+ T cells are human CD4+ T cells, cynomolgus monkey CD4+ T cells, rhesus monkey CD4+ T cells, or a combination thereof.

29. The method of claim 17 , wherein the contacting comprises administering an effective amount of the hexameric protein to a subject.

30. A method of treating cancer in a subject, wherein the cancer is selected from the group consisting of melanoma, renal cell carcinoma, colon carcinoma, mammary carcinoma, and sarcoma, comprising administering to a subject in need of treatment an effective amount of the hexameric protein of claim 9 or the composition of claim 11 .

31. The method of claim 30 , wherein administration of the hexameric protein or composition can inhibit tumor growth, can promote tumor reduction, or both.

32. The method of claim 30 , wherein tumor growth inhibition is achieved in the presence of T-cells.

33. A method of enhancing an immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the hexameric protein of claim 9 , or the composition of claim 11 .

34. The method of claim 30 , wherein the subject is a human subject.

35. A method of inducing expression of ICOS (inducible T-cell costimulator) on T cells, comprising contacting T cells with the hexameric protein of claim 9 , wherein the hexameric protein can specifically bind to OX40 on the surface of the T cells.

36. A method of inducing expression of PD-1 on T cells, comprising contacting T cells with the hexameric protein of claim 9 , wherein the hexameric protein can specifically bind to OX40 on the surface of the T cells.

Assignees

• Medimmune Llc

Inventors

• Damschroder Melissa
• Oberst Michael
• Hammond Scott
• Feng Hui

Classifications

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• C07K2319/73

  containing coiled-coiled motif (leucine zippers) · CPC title

• C07K14/52 Primary

  Cytokines; Lymphokines; Interferons · CPC title

• A61K2039/6056

  Antibodies · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title